[Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2



[Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2

H1HH1S2SS2D3DD3A4AA4V5VV5F6FF6T7TT7N8NN8S9SS9Y10YY10R11RR11K12KK12V13VV13L14LL14K15KK15R16RR16L17LL17S18SS18A19AA19R20RR20K21KK21L22LL22L23LL23Q24QQ24D25DD25I26II26L27LL27

SMILES None
InChIKey None
Sequence HSDAVFTNSYRKVLKRLSARKLLQDIL

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Ligand site mutations VPAC1

No bioactivity data available.

[Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2

H1HH1S2SS2D3DD3A4AA4V5VV5F6FF6T7TT7N8NN8S9SS9Y10YY10R11RR11K12KK12V13VV13L14LL14K15KK15R16RR16L17LL17S18SS18A19AA19R20RR20K21KK21L22LL22L23LL23Q24QQ24D25DD25I26II26L27LL27

Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Ligand site mutations VPAC1

Compound is not listed as a drug.